Crizotinib
| Use attributes for filter ! | |
| Molar mass | 450. 337 g/mol |
|---|---|
| Other names | PF-02341066; 1066 |
| Formula | C21H22Cl2FN5O |
| Elimination half-life | 42 hours |
| License data | EMA |
| FDA | |
| PDB ligand | PDBe |
| DrugBank | DB08700 |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2173535 |
About Crizotinib
Crizotinib is an anti-cancer drug acting as an ALK and ROS1 inhibitor, approved for treatment of some non-small cell lung carcinoma in the US and some other countries, and undergoing clinical trials . . .